Which injection cuts bleeding best in fibroid surgery?

NCT ID NCT07390864

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two drugs, ergometrine and carbetocin, injected into the uterus during fibroid removal surgery to see which reduces blood loss more. Forty women with symptomatic fibroids will be randomly assigned to receive one of the drugs. The goal is to find a better way to control bleeding and reduce the need for blood transfusions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Methylergometrine and Carbetocin (drugs injected into the uterus to reduce bleeding)
What this could lead to: If one drug proves better, it could become a standard way to reduce blood loss during fibroid surgery, lowering the need for transfusions.
What could go wrong: This is a small, early-stage trial with only 40 participants, so results may not apply to everyone. Both drugs have side effects like nausea or changes in blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 48 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 25 to 48 years * Body mass index (BMI) \< 35 kg/m² * Symptomatic uterine fibroids requiring surgical management (e.g., abnormal uterine bleeding, pelvic pain, or pressure symptoms) * Intramyometrial uterine myomas classified as FIGO types 3 to 6, diagnosed by transvaginal ultrasonography or magnetic resonance imaging * Maximum diameter of the largest myoma ≤ 20 cm * Eligible for and scheduled to undergo abdominal myomectomy * Able and willing to provide written informed consent Exclusion Criteria: * FIGO type 0, 1, 2, 7, or 8 myomas (intracavitary, submucosal, pedunculated subserosal, cervical, or adnexal) * History of pelvic inflammatory disease, peritonitis, or significant abdominal or pelvic infection * History of prior uterine surgery * Use of hormonal treatment within 3 months prior to enrollment * Contraindication to methylergometrine or carbetocin, including: * Known drug allergy * Hypertension * Cardiac or pulmonary disease * Chronic endocrine or metabolic disease (e.g., diabetes mellitus) * Renal or hepatic impairment * High risk of bleeding, including: * Known bleeding disorders * Current use of antiplatelet or anticoagulant therapy * Preoperative anemia (hemoglobin \< 10 g/dL) * BMI ≥ 35 kg/m² * Intraoperative conversion from myomectomy to hysterectomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myoma;uterus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hemorrhage myofibroma uterine corpus leiomyoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myoma;uterus

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Which injection cuts bleeding best in fibroid surgery?

What the study statuses mean